Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Satisfaction with Natesto in Male Hypogonadism
NCT02937740Phase 4Completed
- Sponsor
- Acerus Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of natesto in male hypogonadism (2 arms), sponsored by Acerus Pharmaceuticals. Primary endpoint: Patient Satisfaction - Change From Baseline at 4 months. Started Oct 2016; status: completed.
02
Drugs
natesto
03
Conditions
male hypogonadism
Beyond the preview
Go deeper on NCT02937740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937740.